Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0001493
UniProt IDQ92831
Primary gene name(s)KAT2B
Synonym gene name(s)PCAF
Protein nameHistone acetyltransferase KAT2B
Protein functionFunctions as a histone acetyltransferase, HAT to promote transcriptional activation. Has significant histone acetyltransferase activity with core histones, H3 and H4, and also with nucleosome core particles. Also acetylates non-histone proteins, such as ACLY. Inhibits cell-cycle progression and counteracts the mitogenic activity of the adenoviral oncoprotein E1A. In case of HIV-1 infection, it is recruited by the viral protein Tat. Regulates Tat's transactivating activity and may help inducing chromatin remodeling of proviral genes. Acts as a circadian transcriptional coactivator which enhances the activity of the circadian transcriptional activators: NPAS2-ARNTL/BMAL1 and CLOCK-ARNTL/BMAL1 heterodimers. {ECO:0000269|PubMed:10675335, ECO:0000269|PubMed:14645221, ECO:0000269|PubMed:23932781, ECO:0000269|PubMed:8684459, ECO:0000269|PubMed:9707565}.
Subcellular locationNucleus {ECO:0000250}.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: Q92831
Gene Ontology
(Biological Process)
Complete annatation
cell cycle arrest [GO:0007050];
cellular response to insulin stimulus [GO:0032869];
chromatin remodeling [GO:0006338];
histone H3 acetylation [GO:0043966];
histone H3-K9 acetylation [GO:0043970];
internal peptidyl-lysine acetylation [GO:0018393];
negative regulation of cell proliferation [GO:0008285];
negative regulation of cyclin-dependent protein serine/threonine kinase activity [GO:0045736];
Notch signaling pathway [GO:0007219];
N-terminal peptidyl-lysine acetylation [GO:0018076];
peptidyl-lysine acetylation [GO:0018394];
positive regulation of gene expression, epigenetic [GO:0045815];
positive regulation of gluconeogenesis by positive regulation of transcription from RNA polymerase II promoter [GO:0035948];
positive regulation of transcription from RNA polymerase II promoter [GO:0045944];
protein acetylation [GO:0006473];
regulation of protein ADP-ribosylation [GO:0010835];
rhythmic process [GO:0048511];
transcription initiation from RNA polymerase II promoter [GO:0006367];
viral process [GO:0016032]
Gene Ontology
(Molecular Function)
Complete annatation
acetyltransferase activity [GO:0016407];
chromatin binding [GO:0003682];
cyclin-dependent protein serine/threonine kinase inhibitor activity [GO:0004861];
histone acetyltransferase activity [GO:0004402];
histone deacetylase binding [GO:0042826];
lysine N-acetyltransferase activity, acting on acetyl phosphate as donor [GO:0004468];
protein complex binding [GO:0032403];
protein kinase binding [GO:0019901];
RNA polymerase II regulatory region sequence-specific DNA binding [GO:0000977];
transcription coactivator activity [GO:0003713];
transcription cofactor activity [GO:0003712];
transcription factor binding [GO:0008134]
Gene Ontology
(Cellular Component)
Complete annatation
A band [GO:0031672];
actomyosin [GO:0042641];
Ada2/Gcn5/Ada3 transcription activator complex [GO:0005671];
cytosol [GO:0005829];
I band [GO:0031674];
kinetochore [GO:0000776];
nuclear chromatin [GO:0000790];
nucleoplasm [GO:0005654];
nucleus [GO:0005634];
PCAF complex [GO:0000125]
Protein-protein interaction114375
Phylogenetic treeQ92831
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
      unknown
Brass et al., Science, 2008
      unknown
Smith et al., J. Immunol, 2010
      unknown
Interferon-stimulated
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model


DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD3-3.616917009579941.08004383214677e-101.87323597676825e-09
AZA vs. DISU-0.176062849703540.4857016657994530.931429104131977
AZA vs. IL70.3023566758434030.1148615983834220.868694868255551
AZA vs. SAHA-0.4499797630028670.06542598872211990.314086418470457
DISU vs. CD33.429150171962953.75930842011485e-108.34577542338899e-09
DISU vs. IL70.4688973719837820.06257245534366820.329587618555485
DISU vs. SAHA-0.2718911870327480.3501872105670080.72869754931887
DMSO vs. AZA0.01014582501037310.9514762273673971
DMSO vs. CD33.619737616057043.5571590117911e-105.05076347904175e-09
DMSO vs. DISU0.1857093370383140.4459781518737160.886778037833078
DMSO vs. IL70.2987816807704990.09574407637526390.566960876814402
DMSO vs. SAHA-0.4667444034204420.04811449491669030.247307608915652
HIV vs. Mock in Activation0.1352606582229570.9031193611192590.999983755607037
HIV vs. Mock in Latency0.0724687946256660.8379672514258250.999834320637052
IL7 vs. CD33.925538896108641.77335923723376e-124.86882400415747e-11
SAHA vs. CD33.144182922372261.12785040196073e-081.47412884280557e-07
SAHA vs. IL7-0.7546693964786180.002008190562523880.0197184681778898
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change -1.550494511
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) TRUE
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK 0.293467 0.0264741
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
unknown unknown unknown unknown unknown
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

Drugbank ID Drug Name Drug Status Pharmacological Action Drug Action
DB01992 Coenzyme A nutraceutical unknown unknown
DB08186 (3E)-4-(1-METHYL-1H-INDOL-3-YL)BUT-3-EN-2-ONE experimental unknown unknown
DB08291 N-(3-AMINOPROPYL)-2-NITROBENZENAMINE experimental unknown unknown

Protein Secondary Structure       (annotations from PDB)      top

PDB Accession Method Resolution Chain Structure Preview
1CM0 X-ray 2.3Å A/B=493-658.
1JM4 NMR - B=719-832.
1N72 NMR - A=719-832.
1WUG NMR - A=719-832.
1WUM NMR - A=719-832.
1ZS5 NMR - A=719-832.
2RNW NMR - A=719-832.
2RNX NMR - A=719-832.
3GG3 X-ray 2.2Å A/B=715-831.
4NSQ X-ray 2.3Å A/B/C/D=493-658.
5FDZ X-ray 2.4Å A/B=715-831.
5FE0 X-ray 2.3Å A/B=715-831.
5FE1 X-ray 2.2Å A/B=715-831.
5FE2 X-ray 2.2Å A/B=715-831.
5FE3 X-ray 2.1Å A/B=715-831.
5FE4 X-ray 2.1Å A/B=715-831.
5FE5 X-ray 2.1Å A/B=715-831.
5FE6 X-ray 1.7Å A/B=715-831.
5FE7 X-ray 2.0Å A/B=715-831.
5FE8 X-ray 2.1Å A/B=715-831.
5FE9 X-ray 2.3Å A/B=715-831.

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa04330 Notch signaling pathway - Homo sapiens (human)
hsa04919 Thyroid hormone signaling pathway - Homo sapiens (human)
hsa05166 HTLV-I infection - Homo sapiens (human)
hsa05203 Viral carcinogenesis - Homo sapiens (human)
Menu